Life Sciences Tools and Services
Company Overview of PsychoGenics Inc.
PsychoGenics Inc. provides preclinical contract research and drug discovery services. The company offers various in vivo tests in the areas of animal models, anxiety, cognition, depression and sexual function, drug abuse liability, epilepsy, injury and pain, micro-dialysis, motor function, neurogenesis, neurological disorders, schizophrenia and mania, and other areas; and in vitro and ex vivo tests in the areas of electrophysiology, neurochemistry, quantitative western blots and quantitative RT-PCR and ELISA, and receptor occupancy. It also creates a range of drug candidates to address various CNS disorders, such as ADHD, cognitive impairment, depression, psychiatric and neurodegenerative di...
765 Old Saw Mill River Road
Tarrytown, NY 10591
Founded in 1999
Key Executives for PsychoGenics Inc.
Chief Executive Officer and President
Co-Founder, Chairman of the Scientific Advisory Board and Principal Scientific Advisor
Senior Vice President of Behavioral Pharmacology
Compensation as of Fiscal Year 2016.
PsychoGenics Inc. Key Developments
PGI Drug Discovery LLC Announces Drug Discovery Collaboration with Sunovion Pharmaceuticals Inc
Apr 4 16
PGI Drug Discovery LLC announced that a compound identified through its drug discovery collaboration with Sunovion Pharmaceuticals Inc. has achieved a milestone. The compound, SEP-856, is a potential antipsychotic agent with a novel mechanism of action being investigated as a possible treatment for patients with schizophrenia. The preclinical models for SEP-856 suggest that it may have the potential to treat the negative symptoms of schizophrenia.
PsychoGenics Inc. Presents at 1st Annual Neuroscience BioPartnering & Investment Forum, Feb-23-2016
Feb 13 16
PsychoGenics Inc. Presents at 1st Annual Neuroscience BioPartnering & Investment Forum, Feb-23-2016. Venue: The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St, 40th Floor (D Elevator Bank), New York, NY 10007, United States. Presentation Date & Speakers: Feb-23-2016, Emer Leahy, Chief Executive Officer and President.
PsychoGenics Extends its Drug Discovery Collaboration with Sunovion
Sep 14 15
PGI Drug Discovery LLC (PsychoGenics) announced that the Company has extended its drug discovery and development collaboration with Sunovion Pharmaceuticals Inc. (Sunovion) for another four years. In August 2007, PsychoGenics and Sunovion entered into a drug discovery and development agreement to combine their complementary strengths and expertise to screen compound libraries and identify a new generation of treatments for neuropsychiatric disorders. Since then the companies have expanded the scope of the collaboration, which has led to the identification of potential drug candidates including a compound in clinical development.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|